332

LMSVYDNW-IppGT.CSLL~CUCERS (SSCbC) IH 62 Pm fin) M 2 mm8BmMs mIm mu OP CAWBRAPTR- RIImuLcnLLLlm3cmc5lmCLc) B.E. JohnWan, 0.g. Richardmn, R.I. Linnoila, D.J. Venzon, W.J. Kallmy, 0. Andormn, P. Okuniaff, J.C. Pharem, D.C. Ihd.. 19ational Cancmr Inetituto and National Naval Madicsl

,rom April 1973 through Dmcembee 1991, 578 PTS with ~ravioumlv untrmatad SCLC ".re mntared on ntosmectiva th.raPautic trial6 at thm WI-USA. sixty-two-(lli) were cancar-ftea 2 YRS after initiation of thermw. 15 PTS (24%) rein alivm and continually frm of caic-er for 2 to 16 YRS (median 6). 20 of the 62 PTS (32%) daveloped r.curr.nt SCLC 2.0 to 12.2 YRS (median 3.5) after initiation of therapy for SCLC. 7 of the 20 redwa1op.d SCLC in th. initially involvad lobe or regional lymph no&m, 6 in th, initially involvad lobe and dintant mites, 6 in diwtant alto* alone, and 1 in the contralateral lung. Pifteon PTS dwmlopmd 16 cu~cerm other than SCLC in the lung (1 bad 2 primary XWCLC~) 3.5 to 15.5 YRS (mmdian 8) from initiation of therapy. 13 PTS bad hintologically docuunted IISCLC, one a .ar~oma, and 1 . mapectmd ISCLC. Of thm PTS with IWZLC, 10 had mqu-US call carcinema, 2 admnocrrai-. and 1 laroa call carcinema. 9 develonad in tha lung con&lat.ral to the original SCLC, l-in a differant lob* of th. .- lung. 3 in tha ‘ama lobe. and in

at=ga I brma8t cmc.r, and -one with-.tagm IB ovarian CUIC.~, all eucca~~fully treated. An additional PT died of ??rytbrolr~a and bad an incidental NSCLC which is includmd abov., OII. dimd of gmtric canae~-, md 011s of lip Canf.I. Tan bavm diad from caumem unrelated to cancar, 3 from pn8uwnia. 3 from carabrovascular dimam. 3 from mad&n dmrth and 0x1. from a parforated colon. From tilea. data wa concluda that nearly all ~11 cell lung canc.ra drrmloping in PTS mxrviving after treataont for SCLC .pp.ar to be LI.cu~=~c.~.. PTS remain at high risk to dwmlop ??econd ralignmci~a for 10 or more YRS after troatmont for SCLC and are appropriate candidates for chmoprovention studies.

334

A RMDOHISED STUDY OF MXGESTROL ACETATE (XAbA) AND PRBDHISOLCWR (P) FOR ANOREXIA AND WZIQRT LOSS II PATIEtQTS WITH LUNG CANCER. FR Macbeth', A Gregor', B Cottie?. 'Beatson Oncology Centre, Glasgow, 'Western General Hosp., 'Clatterbridge Hosp. Liverpool, UK.

Edinburgh,

The effects of MA (48Omg/m*) and P (lSmg/m*) for 8 weeks on body weight, anorexia, quality of life (QOL) and survival were compared in a random- ised, double-blind, study of patients with lung cancer of any histological type. Patients were evaluated at 4, 8 and 12 weeks.

76 patients were entered of which 72 were eligible for assessment. There was a high incid- ence of early withdrawal from the study because of death and increasing frailty, and most measures of weight, PS and QOL worsened in both groups.

Mean weight at week 12 showed a significant difference in favour of MA of 2.21kg (95% CI +/- 2.52), and there was a consistently significant difference in Rotterdam Symptom Check List score in favour of MA. No other measures of weight, anorexia or QOL showed significant differences.

But the survival was significantly different in the two groups (p=O.O2) with an increased death rate in the patients receiving MA. This result at interim analysis led to early closure of the study.

In this study MA led to a modest improvement in weight compared to P, but was associated with poorer survival.

I l!? Cmbined Strata N - 38 II - 45

CR I47

v N - 17 N - 23 41x 57X

m 53x 61X

jiiah Dose C. CR R

N - 21 14x 19x

N - 22 36X 59x*

?? ?? <0.05 canpared to 6 w/kg dose NS - nm-slgnlflcsnt

zc! 19 Unmr Trmd N - 41 n . 40 44x 6W

lP;,;c)

61X' 73X' 0.001

N - 19 N - I5 53X 60X NS 63X GGX NS

Y * 11 Y * 15 -36x‘- ‘.G& 0.003 59X* MIX* o.M)2

335

THE COMPARISON OF QUALITY OF LIFE WITH MATCHING PAIRED METHOD IN NON-SMALL CELL LUNG CANCER CHEMOTHERAPY-AN INTERIM REPORT- H.Sakai*~,S.Yoneda’~,N.Nukariyai~, K.Kobayashi’), RMatsuoka2~, N.Hoj~),Y.Nishiwakirl,Y.Kwatomr),T.Hoshi”),S.Kitamura41, Y.IshiharaSl,A.Nagai5),J.Kagawa5), XSaitama Cancer Center, z)Koritu Showa Hosp., 3~National Cancer Center East Hosp., +Jichi MedSchoot, s)Tokyo Women’s Med. Colt., Japan

We have developed a new questionnaire measuring the quality of life (QOL) for advanced lung cancer patients in palliative chemotherapy. This questionnatre was consisted of twelve items, five psycholo@cal scale, four physiological scale, active behavior scale for daily living in hospital, linear analog scale and visual face scale on present general condition. The questionnaire have satisfied validity, reliability, sensitivity, test- retest and correlation of various psychological tests and performance status (PS) in lung cancer patients.

Sixty one lung cancer patients measured QOL at the pre- chemotherapy and three times per week after first chemotherapy. To compare the QOL in CDDP ( 80 rr@r# 1 day l)-contained chemo-therapy and CBDCA ( 300 mgm*, day t) contained chemotherapy groups, eight paired patients were selected by sex, age, clinical stage, PS, histological cell type, and response to chemotherapy.

There were no obvious difference between CDDP group and CBDCA group in both physiological and psychological scales. The differences were shown in linear scale and the face scale. These results suggested that the CIOL of non-small cell lung cancer patients might be strongly influenced by the effects of palliative chemotherapy.